Biotech Values

[DewDiligence]

XNPT gets new CEO and business plan:

http://finance.yahoo.com/news/xenoport-announces-plan-focus-growing-200500806.html

…XenoPort will discontinue development of XP23829 on its own and seek to partner this and other high potential development stage assets. In connection with the decision to focus on commercializing HORIZANT, Ronald W. Barrett, Ph.D., has retired as Chief Executive Officer and as a Director of XenoPort, effective immediately. Vincent J. Angotti, Executive Vice President and Chief Operating Officer, who has spearheaded the commercialization of HORIZANT, has been named Chief Executive Officer and has joined XenoPort’s Board of Directors.

XP23829 was on life support (#msg-116988164) and now the plug has been disconnected, evidently.

A sudden departure of a CEO ordinarily warrants a CC, but not this time.